Dynamic simulations on the arachidonic acid metabolic network

PLoS Computational Biology

Volumn 3, Issue 3, 2007, Pages 0523-0530

  Yang, Kun ^a,b   Ma, Wenzhe ^a,b   Liang, Huanhuan ^a   Ouyang, Qi ^b   Tang, Chao ^b   Lai, Luhua ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; DRUG INTERACTIONS; METABOLISM; UNSATURATED FATTY ACIDS;

ANTI-INFLAMMATORY DRUGS; ARACHIDONIC ACIDS; BIOLOGICAL NETWORKS; CYCLOOXYGENASE 2; DRUG DESIGN; DRUG MOLECULES; DYNAMICS SIMULATION; INFLAMMATORY MEDIATORS; LIPOXYGENASES; METABOLIC NETWORK;

ORDINARY DIFFERENTIAL EQUATIONS;

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CAY 10404; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; ARACHIDONIC ACID METABOLISM; ARTICLE; DRUG DESIGN; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MATHEMATICAL ANALYSIS; NEUTROPHIL; SIMULATION; BIOLOGICAL MODEL; CELL CULTURE; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECT; IMMUNOLOGY; LEUKOCYTE; METABOLISM; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CELLS, CULTURED; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION;

EID: 34047216368     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.0030055     Document Type: Article

References (38)

1. Brooks P (1998) Use and benefits of nonsteroidal anti-inflammatory drugs. Am J Med 104: 9S-13S.
2. McCarthy D (1998) Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology. Am J Med 105: 3S-9S.
3. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, et al. (1994) Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A 91: 11202-11206.
4. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, et al. (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 98: 1725-1733.
5. Psaty BM, Furberg CD (2005) COX-2 inhibitors - Lessons in drug safety. N Engl J Med 352: 1133-1135.
6. Wang D, Wang M, Cheng Y, Fitzgerald GA (2005) Cardiovascular hazard and non-steroidal anti-inflammatory drugs. Curr Opin Pharmacol 5: 204-210.
7. Singh D (2004) Merck withdraws arthritis drug worldwide. BMJ 329: 816.
8. Okie S (2005) Raising the safety bar-The FDA's coxib meeting. N Engl J Med 352: 1283-1285.
9. Ray WA, Griffin MR, Stein CM (2004) Cardiovascular toxicity of valdecoxib. N Engl J Med 351: 2767.
10. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080.
11. Sams-Dodd F (2005) Target-based drug discovery: Is something wrong? Drug Discov Today 10: 139-147.
12. Fishman MC, Porter JA (2005) Pharmaceuticals: A new grammar for drug discovery. Nature 437: 491-493.
13. Werner E (2002) Systems biology: The new darling of drug discovery? Drug Discov Today 7: 947-949.
14. Kitano H (2002) Computational systems biology. Nature 420: 206-210.
15. Hood L (2003) Systems biology: Integrating technology, biology, and computation. Mech Ageing Dev 124: 9-16.
16. Butcher EC, Berg EL, Kunkel EJ (2004) Systems biology in drug discovery. Nat Biotechnol 22: 1253-1259.
17. Ekins S, Nikolsky Y, Nikolskaya T (2005) Techniques: Application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci 26: 202-209.
18. Jones KC, Mann KG (1994) A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 269: 23367-23373.
19. Somogyi R, Greller LD (2001) The dynamics of molecular networks: Applications to therapeutic discovery. Drug Discov Today 6: 1267-1277.
20. Rajasethupathy P, Vayttaden SJ, Bhalla US (2005) Systems modeling: A pathway to drug discovery. Curr Opin Chem Biol 9: 400-406.
21. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, et al. (2006) From genomics to chemical genomics: New developments in KEGG. Nucleic Acids Res 34: D354-D357.
22. Shak S, Goldstein IM (1984) Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. J Biol Chem 259: 10181-10187.
23. Kishimoto K, Nakamura M, Suzuki H, Yoshimoto T, Yamamoto S, et al. (1996) Suicide inactivation of porcine leukocyte 12-lipoxygenase associated with its incorporation of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid derivative. Biochim Biophys Acta 1300: 56-62.
24. Crooks SW, Stockley RA (1998) Leukotriene B4. Int J Biochem Cell Biol 30: 173-178.
25. Pouliot M, Gilbert C, Borgeat P, Poubelle PE, Bourgoin S, et al. (1998) Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J 12: 1109-1123.
26. Abraham WM, Laufer S, Tries S (1997) The effects of ML 3000 on antigeninduced responses in sheep. Pulm Pharmacol Ther 10: 167-173.
27. Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, et al. (1998) New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: Variations at the 5 position. J Med Chem 41: 3515-3529.
28. Ulbrich H, Soehnlein O, Xie X, Eriksson EE, Lindbom L, et al. (2005) Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow. Biochem Pharmacol 70: 30-36.
29. Vila L (2004) Cyclooxygenase and 5-lipoxygenase pathways in the vessel wall: Role in atherosclerosis. Med Res Rev 24: 399-424.
30. Klegeris A, McGeer PL (2002) Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 23: 787-794.
31. Rainsford KD (2001) The ever-emerging anti-inflammatories. Have there been any real advances? J Physiol Paris 95: 11-19.
32. Davies NM, Skjodt NM (1999) Clinical pharmacokinetics of meloxicam. A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug. Clin Pharmacokinet 36: 115-126.
33. Alvaro-Gracia JM (2004) Licofelone - Clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis. Rheumatology (Oxford) 43 (Supplement 1): i21-25.
34. Bias P, Buchner A, Klesser B, Laufer S (2004) The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: Results from a randomized, controlled trial. Am J Gastroenterol 99: 611-618.
35. Hjorth R, Jonsson AK, Vretblad P (1981) A rapid method for purification of human granulocytes using percoll. A comparison with dextran sedimentation. J Immunol Methods 43: 95-101.
36. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard JW (1990) MK886, a potent and specific leukotriene biosynthesis inhibitor blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 265: 1436-1442.
37. Parashar B, Latha Shankar S, O'Guin K, Butler J, Vikram B, et al. (2005) Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor. J Neurooncol 71: 141-148.
38. Liang T, Qin Y, Liang N, Huang R (2003) The anti-inflammatory effect of total flavonoids isolated from Platychadus orientalis and its mechanism. Chinese Pharmacol Bull 19: 1407-1410.